AI Drug Discovery for Pharma and Biotech

Drug discovery

145

drugs

With orphan designations

Overview

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease characterized by irreversible lung scarring (usual interstitial pneumonia pattern) and declining lung function [1][6]. Median survival is 2–5 years post-diagnosis, with respiratory failure as the primary cause of death [6][16]. Diagnosis requires exclusion of secondary causes and confirmation via HRCT or histopathology [6][16].

Population

  • Primarily affects adults >50 years (mean age 65–70), with incidence rising sharply after age 55 (19.3/100,000 person-years in 55–64 year-olds) [2][17]

  • Male predominance (incidence ratio 1.08 male:female) [2][7]

  • Estimated US prevalence: 42.7–63/100,000 [4][12]

Burden

  • Median survival 2–5 years; comparable to aggressive cancers [6][16]

  • Annual US healthcare costs ~$20,000/patient (2.5–3.5× national average) [4]

  • 61.7/100 mean EQ-5D QoL score, with 24–64% annual hospitalization rates [9][11]

Therapies

  • Antifibrotics (pirfenidone, nintedanib) to slow progression (30% reduction in FVC decline) [5][13]

  • Supportive care: oxygen therapy, pulmonary rehabilitation, symptom management [1][5]

  • Lung transplantation (only curative option; 1,400+ performed at leading centers) [1][6]

Categories: rare respiratory diseases, rare transplant-related disorders

Research Papers

6,511 drug discovery papers about Idiopathic pulmonary fibrosis, with 2 first-in-class and 120 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

6,511 drug discovery papers about Idiopathic pulmonary fibrosis, with 2 first-in-class and 120 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-30 | Folate metabolism-related gene signature reveals prognostic and immunological characteristics in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by irreversible lung remodeling and poor prognosis. Metabolic dysregulation, has emerged as a critical contributor to fibroblast activation and immune dysfunction.  Methods: Transcriptome datasets from the Gene Expression Omnibus were used, with GSE70866-GPL14550 as the training cohort and GSE70866-GPL17077 as an independent validation cohort. Differential expression analysis and weighted gene co-expression network analysis were performed to identify IPF-associated modules. Intersection of differentially expressed genes, hub genes from key modules, and curated FMRGs yielded candidate metabolic signatures. Cox regression and least absolute shrinkage and selection operator analysis were applied to construct a multi-gene prognostic model. Functional enrichment, Gene Set Enrichment Analysis, single-sample Gene Set Enrichment Analysis, and Cell-type deconvolution was performed using CIBERSORT were used to characterize biological pathways and immune infiltration patterns. A nomogram integrating clinical features was built and validated. Upstream transcription factor and competing endogenous RNA regulatory networks, potential drug-gene interactions, and molecular subtypes were also identified. Ten IPF-related FMRGs were identified through integrated analyses. A four-gene prognostic signature was constructed in the training cohort and externally validated in the independent cohort, effectively stratifying patients into high- and low-risk groups with distinct survival outcomes. High-risk patients exhibited enrichment of epithelial-mesenchymal transition, extracellular matrix remodeling, and cytokine-mediated pathways, accompanied by heightened infiltration of pro-inflammatory and pro-fibrotic immune cells and elevated immune checkpoint expression. The nomogram demonstrated high predictive accuracy and clinical utility. Two metabolic subtypes (Cluster 1/2) were identified, showing significant differences in survival, immune infiltration, checkpoint expression, and pathway activation. This study establishes a folate metabolism-based prognostic signature and reveals distinct metabolic-immune phenotypes and molecular subtypes in IPF, offering novel biomarkers and therapeutic insights. Clinically, the risk score/nomogram may support risk-adapted monitoring and prioritization of high-risk patients for treatment optimization.

Open article ↗



2026-09-30 | Efficacy and safety of extended-release oral opioid for cough in idiopathic pulmonary fibrosis: A systematic review and meta-analysis of randomized controlled trials.

Patients with idiopathic pulmonary fibrosis (IPF) experience a high burden of cough. Currently, no established effective therapy exists for cough in IPF. The overall evidence base of oral extended-release (ER) opioid therapies in this population remains limited. This study aimed to compare the efficacy and safety of ER oral opioids versus placebo for cough in patients with IPF. PubMed, Embase, Cochrane, and ClinicalTrial.gov databases were reviewed for randomized controlled trials (RCTs). The primary outcome was 24-hour objective cough frequency. Secondary outcomes included Evaluating Respiratory Symptoms-Idiopathic Pulmonary Fibrosis (E-RS IPF) cough subscale score, Cough Severity-Numeric Rating Scale (CS-NRS) score. Safety outcomes included serious adverse events and adverse events leading to discontinuation. Three RCTs, including 250 patients, were analyzed. Opioid interventions included ER nalbuphine and morphine. ER opioid statistically significantly improved 24-hour objective cough frequency (GMR 0.46; 95% CI 0.23 to 0.92; p = 0.029), CS-NRS score (MD -1.69; 95% CI -2.55 to -0.84; p < 0.001), and E-RS IPF cough subscale score (MD -0.49; 95% CI -0.89 to -0.09; p = 0.016), compared with placebo. No statistically significant differences were observed for serious adverse events or adverse events leading to discontinuation. ER oral opioids significantly improved cough frequency and patient-reported cough severity and discomfort in patients with IPF, without a significant increase in serious adverse events or treatment discontinuation. Extended-release opioids may be cautiously considered as a therapeutic option for cough in patients with IPF.

Open article ↗



2026-09-30 | Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease closely associated with aging, yet the contribution of cellular senescence to fibrotic remodeling and its therapeutic implications remain incompletely understood. Syringin, a phenylpropanoid glycoside derived from Acanthopanax senticosus, has been reported to possess anti-inflammatory and antioxidant activities, but its role in IPF has not been elucidated. In this study, bulk lung transcriptomic data from the GTEx project and nine IPF cohorts were integrated with IPF scRNA-seq data to characterize senescence-associated fibrotic programs. A systems-level compound prioritization strategy incorporating reversed gene expression scoring, network proximity analysis, drug-likeness and toxicity evaluation was applied to identify candidate molecules. The results revealed a pronounced aging-associated transcriptomic profile in IPF lungs, with strong concordance between age-related and IPF-related gene programs. Single-cell analyses further identified senescent fibroblast populations as key cellular hubs characterized by elevated expression of SASP factors. Syringin was subsequently validated in TGFβ1-stimulated fibroblasts, and a murine model of bleomycin-induced pulmonary fibrosis. Syringin consistently attenuated fibroblast activation, cellular senescence markers, and pulmonary fibrosis in vivo and in vitro. Mechanistically, syringin markedly reversed the activation of replication stress-associated signaling pathways. Molecular docking and CETSA suggested a potential interaction between syringin and CHK1. Furthermore, CHK1 knockdown partially abrogated the regulatory effects of syringin on the ATR/CHK1-p53 signaling cascade, supporting CHK1 as a functional mediator of syringin activity. Collectively, these findings identify syringin as a natural small molecule with anti-senescent and anti-fibrotic properties, and may represent a potential therapeutic strategy for IPF.

Open article ↗



2026-09-29 | Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources.

Antifibrotic therapies nintedanib and pirfenidone slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF). However, both medications are often poorly tolerated, leading to dose reductions and discontinuations in practice. How do antifibrotic dose changes (reductions or cessations) affect disease progression in IPF? This retrospective study analyzed data for patients with IPF who initiated antifibrotic therapy using two US data sources: the multicenter Pulmonary Fibrosis Foundation Patient Registry (Registry) and Duke University Health System electronic health records (EHR). Antifibrotic dose groups were defined as full dose, reduced dose for ≥3 months, or stopped therapy for ≥3 months. Associations between antifibrotic dose group, a time-varying exposure, and IPF progression, defined as composite ≥10% decline in ppFVC, all-cause hospitalization, lung transplant, or death, were analyzed by Cox proportional-hazards models adjusted for demographics and lung function. Over a median (25th/75th percentile) follow-up of 30.0 (17.5/30.0) months in the Registry and 14.0 (7.4/29.6) months in the EHR, 347/545 (63.7%) and 609/1,027 (59.3%) patients remained on full dose, respectively. Event rates for progression per 100 person-years in patients on full dose, reduced dose, or discontinuation were 39.74, 46.62, and 70.69, respectively, in the Registry and 44.82, 40.46, and 41.72 in the EHR. Time to progression did not differ significantly between patients who reduced or stopped antifibrotics and those who remained on full dose in the Registry (HR 1.17 [95% CI 0.90-1.52] for dose reduction, 1.51 [1.04-2.18] for discontinuation; P=.073) and EHR (HR 0.87 [0.69-1.09], 0.94 [0.66-1.36]; P=.476), respectively. Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability. Disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-tolerated IPF therapies.

Open article ↗



2026-09-27 | Mechanofusion-assisted magnesium stearate surface modification enhances dispersion and aerodynamic performance of carrier-based nintedanib inhalable dry powder formulations.

Oral administration of nintedanib, a multi-receptor tyrosine kinase inhibitor for idiopathic pulmonary fibrosis, is associated with gastrointestinal side effects and limited lung targeting. Pulmonary delivery using dry powder inhalers (DPIs) offers a promising alternative, but the strong cohesiveness of drug microparticles hinders aerosolization and deep lung deposition. This study developed carrier-based DPI systems using mechanofusion with magnesium stearate (MgSt) at 0%, 1%, and 5% (w/w) and compared their physicochemical and aerodynamic performance with physical mixtures. Respirable nintedanib particles produced by jet milling were combined with lactose and MgSt to prepare six blends. Solid-state analyses by differential scanning calorimetry, powder X-ray diffraction, and Fourier transform infrared spectroscopy showed that mechanofusion enhanced drug-excipient interactions, with attenuated nintedanib peaks and modified thermal responses, while jet milling largely preserved the crystalline structure of nintedanib. Scanning electron microscopy, energy-dispersive X-ray spectroscopy, and Raman imaging confirmed more uniform adhesion and distribution of nintedanib and MgSt on the carrier surface. Bulk-density-derived flowability indices were numerically lower at higher MgSt contents. Aerodynamic evaluation using a next-generation impactor showed that mechanofusion, particularly with 5% MgSt, achieved higher fine and extra-fine particle fractions, confirming its synergistic role with MgSt in improving pulmonary delivery efficiency. These findings suggest that mechanofusion, particularly when combined with MgSt, is an effective strategy for improving the aerodynamic performance of carrier-based DPI formulations. By reducing particle cohesion and enhancing dispersion, this approach may facilitate more efficient pulmonary delivery of highly cohesive drugs such as nintedanib.

Open article ↗



antibodies
2026-09-24 | Inhibition of Extracellular Tissue Transglutaminase (TG2) Activity Attenuates Development of Pulmonary Fibrosis in a Novel Rabbit Model.

Pulmonary fibrosis is an interstitial scarring disease of the lung characterized by poor prognosis and limited treatment options. Tissue transglutaminase (TG2) is believed to promote lung fibrosis by crosslinking extracellular matrix components and activating latent TGFβ. This study evaluates the contribution of TG2 to pulmonary fibrosis in human lung tissue from donors with idiopathic pulmonary fibrosis (IPF) and in a novel rabbit model of pulmonary silicosis, using a therapeutic TG2 blocking antibody to inhibit extracellular matrix crosslinking. Human IPF tissue expressed elevated levels of TG2 antigen and Tgm2 RNA as detected by in situ hybridization. and antigen. Silica-treated rabbits developed lung fibrosis with increased collagen and increased TG2 enzymatic activity. Treatment with TG2 inhibitory antibody rbBB7, a rabbitized version of the human therapeutic antibody zampilimab, reduced TG2 activity and attenuated fibrosis by 50% when used in either a prevention or treatment strategy, which was associated, with reductions in interstitial collagen accumulation. TG2 has previously been reported to contribute to pulmonary fibrosis in the mouse bleomycin model, leading to the conclusion that TG2 contributes significantly to the pathogenesis of pulmonary fibrosis as demonstrated in human tissue specimens and two independent animal models with different fibrotic stimuli. Blockade of TG2 extracellular crosslinking activity with a therapeutic antibody significantly attenuated the development of fibrosis when given in a prevention strategy or treatment strategy. Blockade of extracellular TG2 activity has exciting therapeutic potential.

Open article ↗



2026-09-17 | Cadherin-11 Regulation of Type II Alveolar Epithelial Cells During Pulmonary Fibrosis.

Type II alveolar epithelial cell (AT2) injury has been hypothesized to contribute to pulmonary fibrosis. Cadherin-11 (CDH11) is a mediator of fibrosis and is upregulated on AT2s during lung fibrosis. Herein, the regulation of the AT2 by CDH11 during pulmonary fibrosis was investigated. CDH11 levels were increased in lung samples from patients with idiopathic pulmonary fibrosis (IPF) compared with those from healthy controls. CDH11 expression was inversely correlated with lung function. Cdh11 deficient mice were compared with wild type mice in the intraperitoneal bleomycin model (IP BLM), and the role of the AT2 was investigated using Cdh11 floxed-SPC-Cre mice and in vitro techniques. In the IP BLM model of pulmonary fibrosis, genetic removal of Cdh11 and CDH11 neutralization with monoclonal antibodies reduced pulmonary fibrosis and expression of epithelial injury and mesenchymal markers. Colocalization studies demonstrated that CDH11 was co-expressed with ⍺-SMA on AT2s during fibrosis and inhibition of CDH11 prevented CDH11 co-expression. Furthermore, CDH11 expression was associated with the expression of the AT2 transitional cell marker KRT8 in both in vivo and in vitro studies. Finally, in vitro studies demonstrated that CDH11 engagement, but not N-cadherin engagement, could drive expression of mesenchymal markers in AT2s. Finally, AT2 selective deletion of Cdh11 reduced pulmonary fibrosis in the IP BLM model, confirming that CDH11 regulates the AT2 during the development of lung fibrosis. These data demonstrate that CDH11 is a key regulator of AT2 injury and mesenchymal gene expression during the development of lung fibrosis.

Open article ↗



2026-09-16 | Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) of unclear etiology. Dupilumab, a humanized monoclonal antibody binding to interleukin-4 receptor alpha (IL-4Rα), suppresses both IL-4 and IL-13 signaling pathways. However, the therapeutic potential in IPF is unclear. This research aimed to evaluate the antifibrotic efficacy of dupilumab and illustrate the underlying mechanisms. The antifibrotic efficacy of dupilumab was assessed both in vitro and in vivo. In vitro, a fibroblast activation model and a macrophage-fibroblast co-culture model were established. In vivo, pulmonary fibrosis was induced in C57BL/6 mice by intratracheal bleomycin injection. Lung function, micro-computed tomography (micro-CT), histopathology, inflammatory responses, and fibrosis-related signaling pathways were assessed. Dupilumab significantly suppressed TGF-β1-induced fibroblast activation. In the macrophage-fibroblast coculture system, dupilumab inhibited the profibrotic phenotype of IL-4/IL-13-stimulated macrophages, as well as macrophage-induced myofibroblast activation. In bleomycin-challenged mice, dupilumab improved pulmonary function, alleviated radiographic and histopathological fibrosis, reduced inflammatory cell counts and inflammatory cytokine levels in bronchoalveolar lavage fluid. Mechanistically, dupilumab suppressed activation of both the TGF-β1/Smad and JAK/STAT pathways in fibrotic lung tissues. Dupilumab attenuates pulmonary fibrosis by disrupting profibrotic macrophage-fibroblast crosstalk and suppressing fibroblast activation. In preclinical models, dupilumab mitigated BLM-induced pulmonary inflammation and early-stage fibrosis in mice and inhibited the TGF-β1-Smad and JAK-STAT signal transduction cascades. These findings identify IL-4Rα-mediated signaling as a promising intervention point in pulmonary fibrosis and support further investigation of dupilumab as a candidate therapy for fibrotic lung diseases.

Open article ↗



2026-09-14 | Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report.

There is no established treatment for relapsed SCLC in patients with interstitial lung disease. We report the case of a 67-year-old man with idiopathic pulmonary fibrosis (IPF) receiving nintedanib who developed a postoperative relapse of SCLC. After cisplatin plus etoposide therapy, the patient developed an acute exacerbation of IPF, which improved with corticosteroid therapy. However, pleural dissemination and pulmonary metastases progressed, leading to the initiation of tarlatamab. During follow-up, transient ground-glass opacities appeared around pulmonary metastases. These opacities resolved, and tumor shrinkage was observed. The patient achieved a partial response without new toxicities, and the therapy was ongoing. Immunohistochemical analysis using an anti-delta-like ligand 3 antibody (SP347) reported strong expression in tumor cells but no detectable expression in adjacent normal or fibrotic lung tissue. This finding provides a possible biological rationale. This case suggests that tarlatamab may be a potential therapeutic option in selected patients with relapsed SCLC complicated by IPF.

Open article ↗



2026-08-26 | A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is closely associated with fibroblast proliferation, macrophage polarization, and the accumulation of extracellular matrix (ECM). Targeting CSF-1R can rebalance macrophages, reduce ECM deposition, and block pro-fibrotic signaling. A Fab fragment targeting CSF-1R was screened via phage display. After sequence optimization, it was constructed into an IgG1 antibody (BC006). In vitro activity, domain binding, and signaling blockade were investigated, and in vitro safety indicators were evaluated. Efficacy was assessed using an induced IPF organoid-on-a-chip and bleomycin-induced mouse model. In vivo safety evaluation was conducted in cynomolgus monkeys. BC006 showed an EC50 value of 226 ± 57 nM and a KD of 30 ± 2 nM. It specifically bound to the Ig4-5 domain of CSF-1R by inhibiting receptor dimerization without blocking ligand binding. It could dose-dependently inhibit the differentiation of monocytes into M2 macrophages and exert anti-IPF effects. In the induced IPF organoid-on-a-chip model, BC006 maintained lung barrier function and decreased α-SMA and Collagen I. It also improved lung function and attenuated the degree of fibrosis in the mouse model. Moreover, BC006 had no ADCC, CDC, cytokine release, or hemagglutination, and demonstrated favorable safety profiles in cynomolgus monkeys. BC006 is a novel anti-fibrosis antibody specifically targeting the CSF-1R Ig4-5 domain and offers a new therapeutic strategy for IPF.

Open article ↗



cell therapies
2026-09-23 | The gut-lung axis in respiratory diseases: Mechanisms, microbiome dysbiosis, and therapeutic implications. A comprehensive review.

The gut and lung, though anatomically distinct, are connected through a dynamic, bidirectional communication network known as the gut-lung axis, whereby intestinal microbiota, immune cells, and microbial metabolites regulate pulmonary immunity and homeostasis, while pulmonary perturbations reciprocally alter gut microbial composition and barrier integrity. This narrative review synthesises current evidence on the mechanisms underlying this crosstalk, including immune cell trafficking, short-chain fatty acid and other microbial metabolite signalling, vagal neuroimmune communication, and epigenetic regulation of gut and lung tissues. A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and Cochrane Library from inception to March 2025, supplemented by manual reference screening, yielding 146 included studies. We examine disease-specific patterns of gut dysbiosis and altered gut-lung signalling across asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, respiratory infections, COVID-19 and post-COVID sequelae, obstructive sleep apnoea, and lung cancer, alongside the reverse pathway by which pulmonary disease and critical illness disrupt intestinal homeostasis. We further review microbiome-targeted therapeutic strategies, including probiotics, prebiotics, dietary interventions, faecal microbiota transplantation, and vagus nerve stimulation, and discuss their current evidentiary limitations. Persistent challenges include predominantly observational study designs, inconsistent methodology, limited multi-omics integration, and a paucity of human mechanistic data. We conclude that the gut-lung axis represents a central, bidirectional framework for understanding respiratory disease pathogenesis, and that future progress will depend on longitudinal, multi-omics, and microbiome-stratified interventional studies to enable precision, microbiome-informed respiratory therapeutics.

Open article ↗



2026-09-08 | Multiomic analysis identifies T cell subsets and mechanisms of epithelial interaction in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by progressive scarring and respiratory failure. While T cells are elevated in IPF lungs, their contributions to fibrosis beyond inflammation remain poorly understood. Here, we performed multiplex imaging and single-cell RNA and protein profiling on about 90,000 CD3+ T cells from control and fibrotic lungs, revealing 11 distinct subsets of CD4+ and CD8+ T cells, including a rare CD56+ regulatory T cell. In addition to increased T cell numbers in severely fibrotic lungs compared with non-diseased controls, we observed CD4+ and CD8+ T cells localized near epithelial cells and in niches of abnormal epithelium. CXCR4/MIF signaling emerged as a central axis mediating T cell-epithelial interactions, while epidermal growth factor receptor (EGFR) and TGF-β pathways dominated in multiple T cell subsets. Our findings support the concept that T cells in IPF adopt nonclassical activation patterns that are driven by epithelial interactions within the fibrotic microenvironment. These studies provide a foundation for exploring alternative therapeutic strategies in IPF lungs by modulating T cell behavior and communication networks.

Open article ↗



2026-08-12 | Toxicologic Evaluation of RC-0315, a Mesenchymal Stem Cell-Derived Secretome, Following Repeated Intratracheal Administration in Mice.

RC-0315 is a chemotherapy-exposed mesenchymal stem cell-derived secretome developed as a potential advanced therapy for idiopathic pulmonary fibrosis (IPF). A Good Laboratory Practice (GLP)-compliant repeated-dose toxicity study was conducted to evaluate the safety of RC-0315 following intratracheal (ITR) instillation in immunocompetent ICR and SCID mice. Animals received two cycles of three repeated ITR instillations of RC-0315 performed within a 7-day period and separated by a two-week interval. Mice were assigned to saline, vehicle, low-dose, or high-dose groups and were monitored for 3 days (main phase) or 13 weeks (recovery phase) post last administration. No test article-related mortality or toxic clinical signs were observed in either strain. Clinical pathology parameters, body weight, food consumption, and ophthalmologic findings remained within normal limits, with no dose-dependent alterations. Histopathological examination revealed no RC-0315-related adverse findings in the lungs or other organs, and no local toxicity was evident at the site of administration. These findings support the favorable safety profile of RC-0315 when administered via the clinically intended route.

Open article ↗



2026-08-05 | Human Embryonic Stem Cell-Derived Immunity-And-Matrix-Regulatory Cells Attenuate Pulmonary Fibrosis via MMP1-Mediated Collagen Degradation.

Currently, no targeted therapy exists for idiopathic pulmonary fibrosis (IPF). The hallmark pathological feature of excessive extracellular matrix (ECM) deposition severely undermines the efficacy of mesenchymal stem cell (MSC)-based treatments. While existing MSC therapeutic strategies primarily focus on modulating inflammation in early stages, they have not yet established precise interventions addressing the core pathological mechanism-ECM dysregulation. Previous studies demonstrated the therapeutic potential of human embryonic stem cell (hESCs)-derived immunity-and-matrix-regulatory cells (IMRCs) in lung injury and fibrosis models. However, the critical biomarkers and underlying mechanisms mediating IMRCs' efficacy in IPF remain poorly understood. In this study, we generated MMP1 knockout IMRCs (IMRCs-MMP1 KO) using CRISPR-based gene editing. We then characterized whether MMP1 ablation affected key properties of IMRCs, including cell morphology, proliferation, migration, marker protein expression, transcriptomic profile, and cytokine secretion. Subsequently, the ability of IMRCs-MMP1 KO to degrade collagen was tested using in vivo and in vitro pulmonary fibrosis models. MMP1 knockout was successfully achieved and did not compromise typical IMRC characteristics or impair their immunomodulatory capacity. However, MMP1 deficiency significantly attenuated the ability of IMRCs to degrade TGF-β1-induced collagen I deposition in A549 cells. Importantly, wild-type IMRCs demonstrated superior therapeutic efficacy in ameliorating bleomycin-induced lung injury and fibrosis in mice compared with IMRCs-MMP1 KO. Furthermore, IMRCs exhibited significantly greater capability to directly degrade the pericellular collagen I and modulate fibroblasts' activation progression within fibrotic lung tissues in a MMP1-dependent manner. In summary, our data establish that MMP1 plays an essential functional role in IMRC-mediated attenuation of PF. MMP1 thus represents a key therapeutic biomarker for IMRC-based treatment. This work provides a foundation for developing stem cell therapies tailored to the pathological features of IPF, potentially enabling adaptive treatment strategies.

Open article ↗



2026-07-28 | The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.

The mammalian respiratory system stands as a frontline barrier, constantly exposed to environmental insults, balancing defensive immunity with gas exchange. Historically considered sterile, the lung harbors a dynamic, low-biomass microbiome that evolves continuously in response to pulmonary pathologies. Accumulating evidence underscores that respiratory health and structural recovery are not autonomous but are critically integrated with distal microbial systems, especially the intestinal tract, through the gut-lung axis (GLA). This review characterizes the GLA as a bidirectional communication highway fueled by immune pathways, microbial metabolites, and direct microbial translocations. During acute or chronic injuries, such as COVID-19, COPD, asthma, idiopathic pulmonary fibrosis (IPF) and lung cancer, the gut microbiota serves as a remote metabolic "rheostat". It delivers pivotal signaling molecules, such as short-chain fatty acids (SCFAs) and tryptophan metabolites (indoles), that could shape the local microenvironment in which the respiratory epithelium undergoes functional repair or maladaptive, fibrotic remodeling. Mechanistically, gut-derived butyrate enhances mitochondrial activity in alveolar epithelial cells, while resident progenitors, such as Alveolar Type 2 (AT2) cells, depend on intact mitochondrial fatty acid oxidation for proper regenerative differentiation. Conversely, critical lung illness disrupts this homeostasis via a "pathological circuit," where severe pulmonary inflammation drives gut permeability, fecal dysbiosis, and the subsequent translocation of pathogen-associated molecular patterns (PAMPs, such as LPS) or gut-associated bacteria back into the pulmonary circulation. This review highlights the systemic nature of lung regeneration, which likely depends heavily on intestinal health through the GLA. Ultimately, leveraging these remote microbial networks through precision postbiotic supplementation, dietary priming, or microbiota transplantation represents a crucial frontier in precision medicine to promote definitive alveolar repair.

Open article ↗



oligonucleotides
2026-09-23 | Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities.

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a progressive interstitial lung disease caused by failed epithelial repair, persistent fibroblast activation, immune dysregulation, and extracellular matrix (ECM) remodeling. Nintedanib and pirfenidone slow functional decline but do not reverse established fibrosis. Small interfering RNA (siRNA) offers sequence-specific silencing of disease-driving genes, but degradation, mucus and ECM barriers, inefficient cellular uptake, and endosomal sequestration restrict its activity in fibrotic lungs. This review examines these barriers alongside the rationale for selecting siRNA targets and nanocarrier platforms. Lipid, polymeric, biomimetic, and inorganic systems are compared in terms of loading, tissue penetration, intracellular release, safety, manufacturing, and clinical feasibility. We also consider single-target and multitarget strategies, pulmonary and systemic administration, disease-model limitations, and early clinical experience. The resulting target-to-delivery framework defines the evidence required before pulmonary siRNA nanomedicines can enter informative clinical testing.

Open article ↗



2026-08-22 | Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis.

Myofibroblast differentiation is a pivotal event in idiopathic pulmonary fibrosis (IPF) and is driven by transforming growth factor-β1 (TGF-β1)-dependent phosphatase and tensin homolog deleted on chromosome 10 (PTEN) destabilization; however, the intermediate regulators remain incompletely defined. We tested three lung fibroblast cell lines (1 normal and 2 IPF derived) and identified the phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 (PREX2)-membrane-associated guanylate kinase inverted 2 (MAGI2) as a critical regulator of myofibroblast differentiation. Loss-of-function analysis of MAGI2 in normal human lung fibroblasts revealed a shift toward a myofibroblast phenotype characterized by abundant α-smooth muscle actin (α-SMA) expression. In vitro experiments revealed increased PREX2 expression and decreased MAGI2 expression in IPF-derived lung fibroblasts compared with those in normal lung fibroblasts. Consistent with this finding, in vivo experiments using bleomycin-induced murine pulmonary fibrosis revealed PREX2 upregulation in contrast to MAGI2 downregulation with the progression of lesions. Notably, PREX2 depletion in IPF-derived cells enhanced MAGI2 expression, mitigating TGF-β1-induced α-SMA expression. Conversely, PREX2 overexpression promoted myofibroblast differentiation, as evidenced by MAGI2 downregulation followed by marked α-SMA expression. The PREX2-targeting suppressive miR-338-3p upregulated MAGI2 expression in vitro and ameliorated bleomycin-induced murine pulmonary fibrosis in vivo. Immunohistochemical staining of PREX2 on lung samples obtained from patients with IPF delineated that PREX2 was exclusively expressed in the fibroblastic foci of IPF-affected lungs. Fluorescence immunostaining revealed PREX2 colocalization with α-SMA in myofibroblasts within fibroblastic foci, corroborating our hypothesis. These findings suggest that MAGI2 acts as a negative regulator of myofibroblast differentiation by stabilizing PTEN, whereas PREX2 is aberrantly expressed in the fibrotic milieu, negatively modulating MAGI2, thereby accelerating pulmonary fibrosis.NEW & NOTEWORTHY In the fibrotic milieu, upregulated phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 (PREX2) and downregulated membrane-associated guanylate kinase inverted 2 (MAGI2) expression were observed as evidenced by in vivo and in vitro analyses. PREX2 was exclusively expressed in fibroblastic foci in lung samples derived from patients with idiopathic pulmonary fibrosis (IPF) and was colocalized with α-smooth muscle actin (α-SMA) in myofibroblasts within these foci. Thus, the aberrantly expressed PREX2-MAGI2 axis modulates myofibroblast differentiation in IPF, whereby PREX2 negatively modulates MAGI2, destabilizing phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and ultimately accelerating pulmonary fibrosis.

Open article ↗



2026-08-19 | ROS-Scavenging Single-Component Polymeric Nanocarriers for Precision siRNA Delivery in Pulmonary Fibrosis Therapy.

Idiopathic pulmonary fibrosis (IPF) is a progressive refractory lung disorder with limited effective therapies. Although RNA interference (RNAi) holds promise for IPF treatment, current delivery systems are hampered by complex preparation, redundant components, and an inability to modulate oxidative stress, which severely compromises their therapeutic outcomes. Herein, we design a single-component, lung-targeted nanosystem, PPN@siIL11, that simplifies formulation while integrating dual functions of efficient siRNA delivery and reactive oxygen species (ROS) scavenging. Upon intravenous administration, this streamlined platform exhibits enhanced pulmonary accumulation, effectively silences the profibrotic gene IL11, and suppresses fibroblast-to-myofibroblast transdifferentiation and excessive extracellular matrix deposition. Concurrently, it scavenges overproduced ROS to alleviate oxidative stress-mediated lung damage. Both in vitro and in vivo results demonstrate the potent anti-fibrotic efficacy of PPN@siIL11. By overcoming critical drawbacks of conventional multi-component carriers, this multifunctional single-component platform establishes a translatable approach for RNAi-based IPF therapy, with potential applicability to other lung diseases.

Open article ↗



2026-08-13 | The telomeric DNA damage response as a therapeutic target in idiopathic pulmonary fibrosis.

Telomere dysfunction and the telomeric DNA damage response (tDDR) activation correlate with aging and age-related diseases, including idiopathic pulmonary fibrosis (IPF). However, a causal role for tDDR in IPF pathogenesis has not been determined. IPF patients frequently bear germline mutations in telomerase genes, critically short telomeres, and markers of tDDR and cellular senescence. We previously demonstrated that telomeric antisense-oligonucleotides (tASOs) targeting telomeric non-coding RNAs are selective tDDR inhibitors. Here, we employed late-generation telomerase knockout mice as a genetic model of IPF. Systemic tASOs treatment reduces DDR-including in stem/progenitor cells-inflammation, and lung fibrosis in young, adult, and old mice. Markers of DDR correlate with lung pathology, and tDDR inhibition normalizes molecular and pathological phenotypes, uncoupling telomere lengths from their deleterious consequences. Transcriptomic changes in telomerase knockout mice recapitulate those observed in normal aged mice and in IPF patients, and they are reversed upon tDDR inhibition. These results highlight the pathogenic causative relevance of tDDR activation in IPF pathogenesis and support tASOs as a promising therapeutic strategy for IPF and for telomere biology diseases.

Open article ↗



2026-08-03 | Mannose-modified tobacco mosaic virus-mediated macrophage regulation inhibits pulmonary fibrosis progression.

Idiopathic pulmonary fibrosis (IPF) is a chronic disease, causing irreversible lung scarring and respiratory failure. CD206+ M2 macrophages play a key role in its progression. In this study, we utilize the pro-inflammatory properties of plant viruses to develop a mannose-modified tobacco mosaic virus nanoparticle (TMV-OEG8-Man), which targets and reprograms profibrotic macrophages to inhibit IPF. TMV-OEG8-Man alters the CD206+ M2 macrophage phenotype in vitro, suppressing profibrotic genes (Mrc1, Spp1, Ccr2) and signaling pathways (MAPK, TGF-beta, PI3K-Akt, mTOR, Wnt), thereby reducing the transition of fibroblasts to myofibroblasts. When administered via aerosol, TMV-OEG8-Man achieves prolonged lung retention with minimal systemic exposure. In mice with bleomycin-induced pulmonary fibrosis, a single dose during fibroproliferation attenuated fibrosis progression, increasing survival rate from 50% to 100%, and preserving lung architecture. This study establishes plant viral nanoparticles as a macrophage reprogramming strategy with therapeutic potential for organ fibrosis.

Open article ↗



other
2026-09-18 | Genetically predicted GLP-1R expression and idiopathic pulmonary fibrosis: A Mendelian randomization mediation study of JAKMIP3 and pulmonary function.

ObjectiveTo evaluate the association between genetically predicted GLP-1R expression and idiopathic pulmonary fibrosis and to explore potential mediation through JAKMIP3 and pulmonary-function traits using Mendelian randomization.MethodsWe conducted a two-sample drug-target cis-Mendelian randomization study using Genotype-Tissue Expression lung cis-expression quantitative trait locus summary data as genetic proxies for GLP-1R expression and FinnGen R5 summary data (1028 cases and 196,986 controls; n = 198,014) for idiopathic pulmonary fibrosis. Type 2 diabetes mellitus served as a positive control, and a targeted panel of circulating molecular and pulmonary-function traits was evaluated using two-step Mendelian randomization. Primary estimates were obtained using inverse-variance weighting, with complementary estimators and sensitivity analyses. For the European-ancestry pulmonary function analyses, we used measured forced expiratory volume in 1 s (GCST90691840), forced vital capacity (GCST90691839), and peak expiratory flow (GCST90691841) genome-wide association studies, each including 383,471 participants.ResultsHigher genetically predicted GLP-1R expression was associated with a lower risk of idiopathic pulmonary fibrosis on inverse-variance weighted analysis (odds ratio = 0.740, 95% confidence interval: 0.632-0.866, p = 1.83 × 10-4). The positive-control analysis supported the biological coherence of the GLP1R expression proxy (type 2 diabetes mellitus, odds ratio = 0.630). JAKMIP3 was identified as a candidate circulating protein mediator, with a mediation proportion of 9.8%. In the European-ancestry pulmonary function analyses, forced expiratory volume in 1 s, forced vital capacity, and peak expiratory flow showed mediation proportions of 14.2%, 22.6%, and 11.8%, respectively, with the largest estimate observed for forced vital capacity.ConclusionsThe findings support an association between genetically predicted higher GLP-1R expression and lower risk of idiopathic pulmonary fibrosis and identify JAKMIP3 and pulmonary-function traits as candidate intermediates. These results provide a rationale for mechanistic and clinical studies evaluating glucagon-like peptide-1 receptor-related pathways in idiopathic pulmonary fibrosis.

Open article ↗



2026-09-15 | Integrated Bioinformatics and Experimental Validation to Identify Shared Sialylation-Related Signatures in Emphysematous and Fibrotic Lung Disease.

Emphysema and pulmonary fibrosis represent distinct patterns of chronic lung remodeling but may share molecular and cellular abnormalities. In this study, we analyzed public transcriptomic datasets of chronic obstructive pulmonary disease, emphysema, and idiopathic pulmonary fibrosis from the Gene Expression Omnibus database to explore shared disease-related signatures. Weighted gene co-expression network analysis and differential expression analysis were used to identify common molecular alterations, followed by functional enrichment, protein-protein interaction network construction, hub gene screening, immune infiltration analysis, transcription factor prediction, and single-cell RNA-sequencing validation. The integrated analysis revealed overlapping signatures related to cell adhesion, extracellular matrix organization, vascular regulation, immune responses, and epithelial homeostasis. Five hub genes were validated, and ST6GALNAC5 was further prioritized because of its association with sialylation and predominant enrichment in epithelial cells. Given that sialylation has been rarely investigated in pulmonary fibrosis and emphysema, we therefore further investigated ST6GALNAC5-related epithelial sialylation. Experimental validation on tissue samples showed reduced Sambucus nigra agglutinin lectin signals and decreased ST6GALNAC5 expression in lungs with coexisting emphysematous and fibrotic injury. In vitro experiments confirmed that ST6GALNAC5 overexpression attenuated bleomycin-induced epithelial cell injury. Together, these findings identify convergent molecular signatures across emphysematous and fibrotic lung diseases and suggest that impaired epithelial sialylation may represent a previously underappreciated feature of chronic lung remodeling.

Open article ↗



2026-09-13 | Fibronectin's tensional state as a mechanical signature of fibrotic extracellular matrix in idiopathic pulmonary fibrosis models.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with limited treatment options. Emerging evidence suggests that the composition and mechanics of the extracellular matrix (ECM) play a crucial role in IPF pathogenesis; however, biomarkers that indicate altered ECM signatures are scarce. To demonstrate a direct relationship between ECM fiber tension and fibrosis progression, we established an in vitro fibrosis assay using patient-derived fibroblasts and the tension-sensitive fibronectin-binding peptide FnBPA5, whose multivalent binding to fibronectin is impaired by fiber strain. The system was validated using known fibrosis biomarkers at the protein and mRNA levels. Loss of fibronectin fiber tension not only acts as a marker for fibrosis, but as shown here, tension can be restored upon treatment with antifibrotic drugs, concomitant with improved biomarker data. The loss of fibronectin fiber tension was further corroborated ex vivo by probing fibrotic lung cryosections from bleomycin-treated mice with FnBPA5. Taken together, our results highlight the mechanical state of fibronectin fibers as a promising biomarker for IPF.

Open article ↗



2026-09-02 | Multi-omics integration identifies APOE as a metabolic regulator of macrophage-fibroblast crosstalk in idiopathic pulmonary fibrosis.

Aberrant tissue repair and relentless fibroblast activation are hallmark features of idiopathic pulmonary fibrosis (IPF). Although IPF and Alzheimer's disease (AD) share underlying aging-related pathologies, including immune and metabolic dysregulation, the putative genetic mechanisms linking AD susceptibility to pathogenic macrophage remodeling in the fibrotic niche are not fully established. We performed a two-sample Mendelian randomization (MR) analysis to assess the genetic association and potential causal relationship between AD and IPF. Shared hub genes were identified via protein interaction networks. To characterize macrophage heterogeneity and intercellular crosstalk within the IPF microenvironment, we interrogated scRNA-seq data (GSE122960) utilizing Monocle 3 and CellChat algorithms. The functional essentiality of APOE was evaluated bridging computational virtual knockout (scTenifoldKnk) with laboratory in vitro assays. Specifically, downstream transcriptomic shifts and fibroblast activation capacities were validated using APOE-silenced THP-1 macrophages and a Transwell co-culture model with MRC-5 cells. MR estimates indicated that genetic liability to AD is associated with a lower risk of developing IPF. Integrated profiling identified the lipid-metabolism gene APOE as a central hub, specifically enriched in lung macrophages. Pseudotime modeling captured a pathogenic bifurcation in IPF, where macrophages evolve toward a terminal state marked by profound oxidative phosphorylation defects and massive SPP1 secretion. These SPP1+ macrophages primarily activate fibroblasts via CD44 and integrin signaling axes. Furthermore, both virtual simulations and in vitro THP-1 experiments demonstrated that loss of APOE function triggers the hyperactivation of complement (C1QA) and antigen-presentation (HLA-DR) pathways. Co-culture assays ultimately confirmed that APOE ablation in macrophages strongly exacerbates myofibroblast differentiation (elevated α-SMA and collagen I) in adjacent MRC-5 cells. APOE functions as a vital metabolic barrier against pro-fibrotic macrophage polarization in the lung. Disruption of this specific lipid metabolic network is strongly associated with SPP1-driven fibroblast activation and local immune imbalance, providing a theoretical framework that strictly warrants future in vivo investigation to determine its clinical relevance.

Open article ↗



2026-08-25 | Pulmonary delivery of silk fibroin peptides dry powder inhalers for idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a common disease of pulmonary fibrosis with an increasing incidence. Silk fibroin peptides (SFPs) are bioactive substances rich in essential amino acids and possess antioxidant and anti-inflammatory properties; however, their application is limited by drawbacks such as low bioavailability and susceptibility to protein degradation. In this study, spray-drying technology was employed to prepare a silk fibroin peptides dry powder inhaler (SFPs-DPI), followed by characterisation of its physicochemical properties and preliminary in vitro and in vivo studies. The results showed that the yield of SFPs-DPI was 56.86 ± 1.80%, the Carr's index was 25.64 ± 1.71%, the aerodynamic diameter was 2.26 ± 0.04 μm, the moisture content of 0.74%, and the emptying rate was 93 ± 1.61%. In vitro studies demonstrated that SFPs-DPI exhibits good cellular biocompatibility and antioxidant activity. In vivo pharmacodynamic results showed that SFPs-DPI reduced inflammatory infiltration and collagen fibre deposition in the lungs of IPF mice and reduced the expression of type I collagen and α-SMA in lung tissue. Therefore, the physicochemical properties of the SFPs-DPI prepared in this study meet the relevant requirements for dry powder inhalation formulations, providing a preliminary reference for research related to IPF treatment.

Open article ↗



small molecules
2026-09-30 | Folate metabolism-related gene signature reveals prognostic and immunological characteristics in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by irreversible lung remodeling and poor prognosis. Metabolic dysregulation, has emerged as a critical contributor to fibroblast activation and immune dysfunction.  Methods: Transcriptome datasets from the Gene Expression Omnibus were used, with GSE70866-GPL14550 as the training cohort and GSE70866-GPL17077 as an independent validation cohort. Differential expression analysis and weighted gene co-expression network analysis were performed to identify IPF-associated modules. Intersection of differentially expressed genes, hub genes from key modules, and curated FMRGs yielded candidate metabolic signatures. Cox regression and least absolute shrinkage and selection operator analysis were applied to construct a multi-gene prognostic model. Functional enrichment, Gene Set Enrichment Analysis, single-sample Gene Set Enrichment Analysis, and Cell-type deconvolution was performed using CIBERSORT were used to characterize biological pathways and immune infiltration patterns. A nomogram integrating clinical features was built and validated. Upstream transcription factor and competing endogenous RNA regulatory networks, potential drug-gene interactions, and molecular subtypes were also identified. Ten IPF-related FMRGs were identified through integrated analyses. A four-gene prognostic signature was constructed in the training cohort and externally validated in the independent cohort, effectively stratifying patients into high- and low-risk groups with distinct survival outcomes. High-risk patients exhibited enrichment of epithelial-mesenchymal transition, extracellular matrix remodeling, and cytokine-mediated pathways, accompanied by heightened infiltration of pro-inflammatory and pro-fibrotic immune cells and elevated immune checkpoint expression. The nomogram demonstrated high predictive accuracy and clinical utility. Two metabolic subtypes (Cluster 1/2) were identified, showing significant differences in survival, immune infiltration, checkpoint expression, and pathway activation. This study establishes a folate metabolism-based prognostic signature and reveals distinct metabolic-immune phenotypes and molecular subtypes in IPF, offering novel biomarkers and therapeutic insights. Clinically, the risk score/nomogram may support risk-adapted monitoring and prioritization of high-risk patients for treatment optimization.

Open article ↗



2026-09-30 | Efficacy and safety of extended-release oral opioid for cough in idiopathic pulmonary fibrosis: A systematic review and meta-analysis of randomized controlled trials.

Patients with idiopathic pulmonary fibrosis (IPF) experience a high burden of cough. Currently, no established effective therapy exists for cough in IPF. The overall evidence base of oral extended-release (ER) opioid therapies in this population remains limited. This study aimed to compare the efficacy and safety of ER oral opioids versus placebo for cough in patients with IPF. PubMed, Embase, Cochrane, and ClinicalTrial.gov databases were reviewed for randomized controlled trials (RCTs). The primary outcome was 24-hour objective cough frequency. Secondary outcomes included Evaluating Respiratory Symptoms-Idiopathic Pulmonary Fibrosis (E-RS IPF) cough subscale score, Cough Severity-Numeric Rating Scale (CS-NRS) score. Safety outcomes included serious adverse events and adverse events leading to discontinuation. Three RCTs, including 250 patients, were analyzed. Opioid interventions included ER nalbuphine and morphine. ER opioid statistically significantly improved 24-hour objective cough frequency (GMR 0.46; 95% CI 0.23 to 0.92; p = 0.029), CS-NRS score (MD -1.69; 95% CI -2.55 to -0.84; p < 0.001), and E-RS IPF cough subscale score (MD -0.49; 95% CI -0.89 to -0.09; p = 0.016), compared with placebo. No statistically significant differences were observed for serious adverse events or adverse events leading to discontinuation. ER oral opioids significantly improved cough frequency and patient-reported cough severity and discomfort in patients with IPF, without a significant increase in serious adverse events or treatment discontinuation. Extended-release opioids may be cautiously considered as a therapeutic option for cough in patients with IPF.

Open article ↗



2026-09-30 | Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease closely associated with aging, yet the contribution of cellular senescence to fibrotic remodeling and its therapeutic implications remain incompletely understood. Syringin, a phenylpropanoid glycoside derived from Acanthopanax senticosus, has been reported to possess anti-inflammatory and antioxidant activities, but its role in IPF has not been elucidated. In this study, bulk lung transcriptomic data from the GTEx project and nine IPF cohorts were integrated with IPF scRNA-seq data to characterize senescence-associated fibrotic programs. A systems-level compound prioritization strategy incorporating reversed gene expression scoring, network proximity analysis, drug-likeness and toxicity evaluation was applied to identify candidate molecules. The results revealed a pronounced aging-associated transcriptomic profile in IPF lungs, with strong concordance between age-related and IPF-related gene programs. Single-cell analyses further identified senescent fibroblast populations as key cellular hubs characterized by elevated expression of SASP factors. Syringin was subsequently validated in TGFβ1-stimulated fibroblasts, and a murine model of bleomycin-induced pulmonary fibrosis. Syringin consistently attenuated fibroblast activation, cellular senescence markers, and pulmonary fibrosis in vivo and in vitro. Mechanistically, syringin markedly reversed the activation of replication stress-associated signaling pathways. Molecular docking and CETSA suggested a potential interaction between syringin and CHK1. Furthermore, CHK1 knockdown partially abrogated the regulatory effects of syringin on the ATR/CHK1-p53 signaling cascade, supporting CHK1 as a functional mediator of syringin activity. Collectively, these findings identify syringin as a natural small molecule with anti-senescent and anti-fibrotic properties, and may represent a potential therapeutic strategy for IPF.

Open article ↗



2026-09-29 | Association of Antifibrotic Dosing Patterns With Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis in Real-World Data Sources.

Antifibrotic therapies nintedanib and pirfenidone slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF). However, both medications are often poorly tolerated, leading to dose reductions and discontinuations in practice. How do antifibrotic dose changes (reductions or cessations) affect disease progression in IPF? This retrospective study analyzed data for patients with IPF who initiated antifibrotic therapy using two US data sources: the multicenter Pulmonary Fibrosis Foundation Patient Registry (Registry) and Duke University Health System electronic health records (EHR). Antifibrotic dose groups were defined as full dose, reduced dose for ≥3 months, or stopped therapy for ≥3 months. Associations between antifibrotic dose group, a time-varying exposure, and IPF progression, defined as composite ≥10% decline in ppFVC, all-cause hospitalization, lung transplant, or death, were analyzed by Cox proportional-hazards models adjusted for demographics and lung function. Over a median (25th/75th percentile) follow-up of 30.0 (17.5/30.0) months in the Registry and 14.0 (7.4/29.6) months in the EHR, 347/545 (63.7%) and 609/1,027 (59.3%) patients remained on full dose, respectively. Event rates for progression per 100 person-years in patients on full dose, reduced dose, or discontinuation were 39.74, 46.62, and 70.69, respectively, in the Registry and 44.82, 40.46, and 41.72 in the EHR. Time to progression did not differ significantly between patients who reduced or stopped antifibrotics and those who remained on full dose in the Registry (HR 1.17 [95% CI 0.90-1.52] for dose reduction, 1.51 [1.04-2.18] for discontinuation; P=.073) and EHR (HR 0.87 [0.69-1.09], 0.94 [0.66-1.36]; P=.476), respectively. Among patients with IPF, antifibrotic dose reductions and discontinuations were common, likely due to poor drug tolerability. Disease progression occurred in a substantial proportion of patients in both cohorts, regardless of antifibrotic dosing strategy, highlighting the ongoing need for more effective and better-tolerated IPF therapies.

Open article ↗



2026-09-27 | Mechanofusion-assisted magnesium stearate surface modification enhances dispersion and aerodynamic performance of carrier-based nintedanib inhalable dry powder formulations.

Oral administration of nintedanib, a multi-receptor tyrosine kinase inhibitor for idiopathic pulmonary fibrosis, is associated with gastrointestinal side effects and limited lung targeting. Pulmonary delivery using dry powder inhalers (DPIs) offers a promising alternative, but the strong cohesiveness of drug microparticles hinders aerosolization and deep lung deposition. This study developed carrier-based DPI systems using mechanofusion with magnesium stearate (MgSt) at 0%, 1%, and 5% (w/w) and compared their physicochemical and aerodynamic performance with physical mixtures. Respirable nintedanib particles produced by jet milling were combined with lactose and MgSt to prepare six blends. Solid-state analyses by differential scanning calorimetry, powder X-ray diffraction, and Fourier transform infrared spectroscopy showed that mechanofusion enhanced drug-excipient interactions, with attenuated nintedanib peaks and modified thermal responses, while jet milling largely preserved the crystalline structure of nintedanib. Scanning electron microscopy, energy-dispersive X-ray spectroscopy, and Raman imaging confirmed more uniform adhesion and distribution of nintedanib and MgSt on the carrier surface. Bulk-density-derived flowability indices were numerically lower at higher MgSt contents. Aerodynamic evaluation using a next-generation impactor showed that mechanofusion, particularly with 5% MgSt, achieved higher fine and extra-fine particle fractions, confirming its synergistic role with MgSt in improving pulmonary delivery efficiency. These findings suggest that mechanofusion, particularly when combined with MgSt, is an effective strategy for improving the aerodynamic performance of carrier-based DPI formulations. By reducing particle cohesion and enhancing dispersion, this approach may facilitate more efficient pulmonary delivery of highly cohesive drugs such as nintedanib.

Open article ↗



antibodies
2026-09-24 | Inhibition of Extracellular Tissue Transglutaminase (TG2) Activity Attenuates Development of Pulmonary Fibrosis in a Novel Rabbit Model.

Pulmonary fibrosis is an interstitial scarring disease of the lung characterized by poor prognosis and limited treatment options. Tissue transglutaminase (TG2) is believed to promote lung fibrosis by crosslinking extracellular matrix components and activating latent TGFβ. This study evaluates the contribution of TG2 to pulmonary fibrosis in human lung tissue from donors with idiopathic pulmonary fibrosis (IPF) and in a novel rabbit model of pulmonary silicosis, using a therapeutic TG2 blocking antibody to inhibit extracellular matrix crosslinking. Human IPF tissue expressed elevated levels of TG2 antigen and Tgm2 RNA as detected by in situ hybridization. and antigen. Silica-treated rabbits developed lung fibrosis with increased collagen and increased TG2 enzymatic activity. Treatment with TG2 inhibitory antibody rbBB7, a rabbitized version of the human therapeutic antibody zampilimab, reduced TG2 activity and attenuated fibrosis by 50% when used in either a prevention or treatment strategy, which was associated, with reductions in interstitial collagen accumulation. TG2 has previously been reported to contribute to pulmonary fibrosis in the mouse bleomycin model, leading to the conclusion that TG2 contributes significantly to the pathogenesis of pulmonary fibrosis as demonstrated in human tissue specimens and two independent animal models with different fibrotic stimuli. Blockade of TG2 extracellular crosslinking activity with a therapeutic antibody significantly attenuated the development of fibrosis when given in a prevention strategy or treatment strategy. Blockade of extracellular TG2 activity has exciting therapeutic potential.

Open article ↗



2026-09-17 | Cadherin-11 Regulation of Type II Alveolar Epithelial Cells During Pulmonary Fibrosis.

Type II alveolar epithelial cell (AT2) injury has been hypothesized to contribute to pulmonary fibrosis. Cadherin-11 (CDH11) is a mediator of fibrosis and is upregulated on AT2s during lung fibrosis. Herein, the regulation of the AT2 by CDH11 during pulmonary fibrosis was investigated. CDH11 levels were increased in lung samples from patients with idiopathic pulmonary fibrosis (IPF) compared with those from healthy controls. CDH11 expression was inversely correlated with lung function. Cdh11 deficient mice were compared with wild type mice in the intraperitoneal bleomycin model (IP BLM), and the role of the AT2 was investigated using Cdh11 floxed-SPC-Cre mice and in vitro techniques. In the IP BLM model of pulmonary fibrosis, genetic removal of Cdh11 and CDH11 neutralization with monoclonal antibodies reduced pulmonary fibrosis and expression of epithelial injury and mesenchymal markers. Colocalization studies demonstrated that CDH11 was co-expressed with ⍺-SMA on AT2s during fibrosis and inhibition of CDH11 prevented CDH11 co-expression. Furthermore, CDH11 expression was associated with the expression of the AT2 transitional cell marker KRT8 in both in vivo and in vitro studies. Finally, in vitro studies demonstrated that CDH11 engagement, but not N-cadherin engagement, could drive expression of mesenchymal markers in AT2s. Finally, AT2 selective deletion of Cdh11 reduced pulmonary fibrosis in the IP BLM model, confirming that CDH11 regulates the AT2 during the development of lung fibrosis. These data demonstrate that CDH11 is a key regulator of AT2 injury and mesenchymal gene expression during the development of lung fibrosis.

Open article ↗



2026-09-16 | Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) of unclear etiology. Dupilumab, a humanized monoclonal antibody binding to interleukin-4 receptor alpha (IL-4Rα), suppresses both IL-4 and IL-13 signaling pathways. However, the therapeutic potential in IPF is unclear. This research aimed to evaluate the antifibrotic efficacy of dupilumab and illustrate the underlying mechanisms. The antifibrotic efficacy of dupilumab was assessed both in vitro and in vivo. In vitro, a fibroblast activation model and a macrophage-fibroblast co-culture model were established. In vivo, pulmonary fibrosis was induced in C57BL/6 mice by intratracheal bleomycin injection. Lung function, micro-computed tomography (micro-CT), histopathology, inflammatory responses, and fibrosis-related signaling pathways were assessed. Dupilumab significantly suppressed TGF-β1-induced fibroblast activation. In the macrophage-fibroblast coculture system, dupilumab inhibited the profibrotic phenotype of IL-4/IL-13-stimulated macrophages, as well as macrophage-induced myofibroblast activation. In bleomycin-challenged mice, dupilumab improved pulmonary function, alleviated radiographic and histopathological fibrosis, reduced inflammatory cell counts and inflammatory cytokine levels in bronchoalveolar lavage fluid. Mechanistically, dupilumab suppressed activation of both the TGF-β1/Smad and JAK/STAT pathways in fibrotic lung tissues. Dupilumab attenuates pulmonary fibrosis by disrupting profibrotic macrophage-fibroblast crosstalk and suppressing fibroblast activation. In preclinical models, dupilumab mitigated BLM-induced pulmonary inflammation and early-stage fibrosis in mice and inhibited the TGF-β1-Smad and JAK-STAT signal transduction cascades. These findings identify IL-4Rα-mediated signaling as a promising intervention point in pulmonary fibrosis and support further investigation of dupilumab as a candidate therapy for fibrotic lung diseases.

Open article ↗



2026-09-14 | Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report.

There is no established treatment for relapsed SCLC in patients with interstitial lung disease. We report the case of a 67-year-old man with idiopathic pulmonary fibrosis (IPF) receiving nintedanib who developed a postoperative relapse of SCLC. After cisplatin plus etoposide therapy, the patient developed an acute exacerbation of IPF, which improved with corticosteroid therapy. However, pleural dissemination and pulmonary metastases progressed, leading to the initiation of tarlatamab. During follow-up, transient ground-glass opacities appeared around pulmonary metastases. These opacities resolved, and tumor shrinkage was observed. The patient achieved a partial response without new toxicities, and the therapy was ongoing. Immunohistochemical analysis using an anti-delta-like ligand 3 antibody (SP347) reported strong expression in tumor cells but no detectable expression in adjacent normal or fibrotic lung tissue. This finding provides a possible biological rationale. This case suggests that tarlatamab may be a potential therapeutic option in selected patients with relapsed SCLC complicated by IPF.

Open article ↗



2026-08-26 | A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis.

Idiopathic pulmonary fibrosis (IPF) is closely associated with fibroblast proliferation, macrophage polarization, and the accumulation of extracellular matrix (ECM). Targeting CSF-1R can rebalance macrophages, reduce ECM deposition, and block pro-fibrotic signaling. A Fab fragment targeting CSF-1R was screened via phage display. After sequence optimization, it was constructed into an IgG1 antibody (BC006). In vitro activity, domain binding, and signaling blockade were investigated, and in vitro safety indicators were evaluated. Efficacy was assessed using an induced IPF organoid-on-a-chip and bleomycin-induced mouse model. In vivo safety evaluation was conducted in cynomolgus monkeys. BC006 showed an EC50 value of 226 ± 57 nM and a KD of 30 ± 2 nM. It specifically bound to the Ig4-5 domain of CSF-1R by inhibiting receptor dimerization without blocking ligand binding. It could dose-dependently inhibit the differentiation of monocytes into M2 macrophages and exert anti-IPF effects. In the induced IPF organoid-on-a-chip model, BC006 maintained lung barrier function and decreased α-SMA and Collagen I. It also improved lung function and attenuated the degree of fibrosis in the mouse model. Moreover, BC006 had no ADCC, CDC, cytokine release, or hemagglutination, and demonstrated favorable safety profiles in cynomolgus monkeys. BC006 is a novel anti-fibrosis antibody specifically targeting the CSF-1R Ig4-5 domain and offers a new therapeutic strategy for IPF.

Open article ↗



cell therapies
2026-09-23 | The gut-lung axis in respiratory diseases: Mechanisms, microbiome dysbiosis, and therapeutic implications. A comprehensive review.

The gut and lung, though anatomically distinct, are connected through a dynamic, bidirectional communication network known as the gut-lung axis, whereby intestinal microbiota, immune cells, and microbial metabolites regulate pulmonary immunity and homeostasis, while pulmonary perturbations reciprocally alter gut microbial composition and barrier integrity. This narrative review synthesises current evidence on the mechanisms underlying this crosstalk, including immune cell trafficking, short-chain fatty acid and other microbial metabolite signalling, vagal neuroimmune communication, and epigenetic regulation of gut and lung tissues. A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, and Cochrane Library from inception to March 2025, supplemented by manual reference screening, yielding 146 included studies. We examine disease-specific patterns of gut dysbiosis and altered gut-lung signalling across asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, respiratory infections, COVID-19 and post-COVID sequelae, obstructive sleep apnoea, and lung cancer, alongside the reverse pathway by which pulmonary disease and critical illness disrupt intestinal homeostasis. We further review microbiome-targeted therapeutic strategies, including probiotics, prebiotics, dietary interventions, faecal microbiota transplantation, and vagus nerve stimulation, and discuss their current evidentiary limitations. Persistent challenges include predominantly observational study designs, inconsistent methodology, limited multi-omics integration, and a paucity of human mechanistic data. We conclude that the gut-lung axis represents a central, bidirectional framework for understanding respiratory disease pathogenesis, and that future progress will depend on longitudinal, multi-omics, and microbiome-stratified interventional studies to enable precision, microbiome-informed respiratory therapeutics.

Open article ↗



2026-09-08 | Multiomic analysis identifies T cell subsets and mechanisms of epithelial interaction in idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by progressive scarring and respiratory failure. While T cells are elevated in IPF lungs, their contributions to fibrosis beyond inflammation remain poorly understood. Here, we performed multiplex imaging and single-cell RNA and protein profiling on about 90,000 CD3+ T cells from control and fibrotic lungs, revealing 11 distinct subsets of CD4+ and CD8+ T cells, including a rare CD56+ regulatory T cell. In addition to increased T cell numbers in severely fibrotic lungs compared with non-diseased controls, we observed CD4+ and CD8+ T cells localized near epithelial cells and in niches of abnormal epithelium. CXCR4/MIF signaling emerged as a central axis mediating T cell-epithelial interactions, while epidermal growth factor receptor (EGFR) and TGF-β pathways dominated in multiple T cell subsets. Our findings support the concept that T cells in IPF adopt nonclassical activation patterns that are driven by epithelial interactions within the fibrotic microenvironment. These studies provide a foundation for exploring alternative therapeutic strategies in IPF lungs by modulating T cell behavior and communication networks.

Open article ↗



2026-08-12 | Toxicologic Evaluation of RC-0315, a Mesenchymal Stem Cell-Derived Secretome, Following Repeated Intratracheal Administration in Mice.

RC-0315 is a chemotherapy-exposed mesenchymal stem cell-derived secretome developed as a potential advanced therapy for idiopathic pulmonary fibrosis (IPF). A Good Laboratory Practice (GLP)-compliant repeated-dose toxicity study was conducted to evaluate the safety of RC-0315 following intratracheal (ITR) instillation in immunocompetent ICR and SCID mice. Animals received two cycles of three repeated ITR instillations of RC-0315 performed within a 7-day period and separated by a two-week interval. Mice were assigned to saline, vehicle, low-dose, or high-dose groups and were monitored for 3 days (main phase) or 13 weeks (recovery phase) post last administration. No test article-related mortality or toxic clinical signs were observed in either strain. Clinical pathology parameters, body weight, food consumption, and ophthalmologic findings remained within normal limits, with no dose-dependent alterations. Histopathological examination revealed no RC-0315-related adverse findings in the lungs or other organs, and no local toxicity was evident at the site of administration. These findings support the favorable safety profile of RC-0315 when administered via the clinically intended route.

Open article ↗



2026-08-05 | Human Embryonic Stem Cell-Derived Immunity-And-Matrix-Regulatory Cells Attenuate Pulmonary Fibrosis via MMP1-Mediated Collagen Degradation.

Currently, no targeted therapy exists for idiopathic pulmonary fibrosis (IPF). The hallmark pathological feature of excessive extracellular matrix (ECM) deposition severely undermines the efficacy of mesenchymal stem cell (MSC)-based treatments. While existing MSC therapeutic strategies primarily focus on modulating inflammation in early stages, they have not yet established precise interventions addressing the core pathological mechanism-ECM dysregulation. Previous studies demonstrated the therapeutic potential of human embryonic stem cell (hESCs)-derived immunity-and-matrix-regulatory cells (IMRCs) in lung injury and fibrosis models. However, the critical biomarkers and underlying mechanisms mediating IMRCs' efficacy in IPF remain poorly understood. In this study, we generated MMP1 knockout IMRCs (IMRCs-MMP1 KO) using CRISPR-based gene editing. We then characterized whether MMP1 ablation affected key properties of IMRCs, including cell morphology, proliferation, migration, marker protein expression, transcriptomic profile, and cytokine secretion. Subsequently, the ability of IMRCs-MMP1 KO to degrade collagen was tested using in vivo and in vitro pulmonary fibrosis models. MMP1 knockout was successfully achieved and did not compromise typical IMRC characteristics or impair their immunomodulatory capacity. However, MMP1 deficiency significantly attenuated the ability of IMRCs to degrade TGF-β1-induced collagen I deposition in A549 cells. Importantly, wild-type IMRCs demonstrated superior therapeutic efficacy in ameliorating bleomycin-induced lung injury and fibrosis in mice compared with IMRCs-MMP1 KO. Furthermore, IMRCs exhibited significantly greater capability to directly degrade the pericellular collagen I and modulate fibroblasts' activation progression within fibrotic lung tissues in a MMP1-dependent manner. In summary, our data establish that MMP1 plays an essential functional role in IMRC-mediated attenuation of PF. MMP1 thus represents a key therapeutic biomarker for IMRC-based treatment. This work provides a foundation for developing stem cell therapies tailored to the pathological features of IPF, potentially enabling adaptive treatment strategies.

Open article ↗



2026-07-28 | The Gut-Lung Microbiome Axis in Alveolar Stem Cell Regeneration and Lung Repair.

The mammalian respiratory system stands as a frontline barrier, constantly exposed to environmental insults, balancing defensive immunity with gas exchange. Historically considered sterile, the lung harbors a dynamic, low-biomass microbiome that evolves continuously in response to pulmonary pathologies. Accumulating evidence underscores that respiratory health and structural recovery are not autonomous but are critically integrated with distal microbial systems, especially the intestinal tract, through the gut-lung axis (GLA). This review characterizes the GLA as a bidirectional communication highway fueled by immune pathways, microbial metabolites, and direct microbial translocations. During acute or chronic injuries, such as COVID-19, COPD, asthma, idiopathic pulmonary fibrosis (IPF) and lung cancer, the gut microbiota serves as a remote metabolic "rheostat". It delivers pivotal signaling molecules, such as short-chain fatty acids (SCFAs) and tryptophan metabolites (indoles), that could shape the local microenvironment in which the respiratory epithelium undergoes functional repair or maladaptive, fibrotic remodeling. Mechanistically, gut-derived butyrate enhances mitochondrial activity in alveolar epithelial cells, while resident progenitors, such as Alveolar Type 2 (AT2) cells, depend on intact mitochondrial fatty acid oxidation for proper regenerative differentiation. Conversely, critical lung illness disrupts this homeostasis via a "pathological circuit," where severe pulmonary inflammation drives gut permeability, fecal dysbiosis, and the subsequent translocation of pathogen-associated molecular patterns (PAMPs, such as LPS) or gut-associated bacteria back into the pulmonary circulation. This review highlights the systemic nature of lung regeneration, which likely depends heavily on intestinal health through the GLA. Ultimately, leveraging these remote microbial networks through precision postbiotic supplementation, dietary priming, or microbiota transplantation represents a crucial frontier in precision medicine to promote definitive alveolar repair.

Open article ↗



oligonucleotides
2026-09-23 | Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities.

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a progressive interstitial lung disease caused by failed epithelial repair, persistent fibroblast activation, immune dysregulation, and extracellular matrix (ECM) remodeling. Nintedanib and pirfenidone slow functional decline but do not reverse established fibrosis. Small interfering RNA (siRNA) offers sequence-specific silencing of disease-driving genes, but degradation, mucus and ECM barriers, inefficient cellular uptake, and endosomal sequestration restrict its activity in fibrotic lungs. This review examines these barriers alongside the rationale for selecting siRNA targets and nanocarrier platforms. Lipid, polymeric, biomimetic, and inorganic systems are compared in terms of loading, tissue penetration, intracellular release, safety, manufacturing, and clinical feasibility. We also consider single-target and multitarget strategies, pulmonary and systemic administration, disease-model limitations, and early clinical experience. The resulting target-to-delivery framework defines the evidence required before pulmonary siRNA nanomedicines can enter informative clinical testing.

Open article ↗



2026-08-22 | Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis.

Myofibroblast differentiation is a pivotal event in idiopathic pulmonary fibrosis (IPF) and is driven by transforming growth factor-β1 (TGF-β1)-dependent phosphatase and tensin homolog deleted on chromosome 10 (PTEN) destabilization; however, the intermediate regulators remain incompletely defined. We tested three lung fibroblast cell lines (1 normal and 2 IPF derived) and identified the phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 (PREX2)-membrane-associated guanylate kinase inverted 2 (MAGI2) as a critical regulator of myofibroblast differentiation. Loss-of-function analysis of MAGI2 in normal human lung fibroblasts revealed a shift toward a myofibroblast phenotype characterized by abundant α-smooth muscle actin (α-SMA) expression. In vitro experiments revealed increased PREX2 expression and decreased MAGI2 expression in IPF-derived lung fibroblasts compared with those in normal lung fibroblasts. Consistent with this finding, in vivo experiments using bleomycin-induced murine pulmonary fibrosis revealed PREX2 upregulation in contrast to MAGI2 downregulation with the progression of lesions. Notably, PREX2 depletion in IPF-derived cells enhanced MAGI2 expression, mitigating TGF-β1-induced α-SMA expression. Conversely, PREX2 overexpression promoted myofibroblast differentiation, as evidenced by MAGI2 downregulation followed by marked α-SMA expression. The PREX2-targeting suppressive miR-338-3p upregulated MAGI2 expression in vitro and ameliorated bleomycin-induced murine pulmonary fibrosis in vivo. Immunohistochemical staining of PREX2 on lung samples obtained from patients with IPF delineated that PREX2 was exclusively expressed in the fibroblastic foci of IPF-affected lungs. Fluorescence immunostaining revealed PREX2 colocalization with α-SMA in myofibroblasts within fibroblastic foci, corroborating our hypothesis. These findings suggest that MAGI2 acts as a negative regulator of myofibroblast differentiation by stabilizing PTEN, whereas PREX2 is aberrantly expressed in the fibrotic milieu, negatively modulating MAGI2, thereby accelerating pulmonary fibrosis.NEW & NOTEWORTHY In the fibrotic milieu, upregulated phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 (PREX2) and downregulated membrane-associated guanylate kinase inverted 2 (MAGI2) expression were observed as evidenced by in vivo and in vitro analyses. PREX2 was exclusively expressed in fibroblastic foci in lung samples derived from patients with idiopathic pulmonary fibrosis (IPF) and was colocalized with α-smooth muscle actin (α-SMA) in myofibroblasts within these foci. Thus, the aberrantly expressed PREX2-MAGI2 axis modulates myofibroblast differentiation in IPF, whereby PREX2 negatively modulates MAGI2, destabilizing phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and ultimately accelerating pulmonary fibrosis.

Open article ↗



2026-08-19 | ROS-Scavenging Single-Component Polymeric Nanocarriers for Precision siRNA Delivery in Pulmonary Fibrosis Therapy.

Idiopathic pulmonary fibrosis (IPF) is a progressive refractory lung disorder with limited effective therapies. Although RNA interference (RNAi) holds promise for IPF treatment, current delivery systems are hampered by complex preparation, redundant components, and an inability to modulate oxidative stress, which severely compromises their therapeutic outcomes. Herein, we design a single-component, lung-targeted nanosystem, PPN@siIL11, that simplifies formulation while integrating dual functions of efficient siRNA delivery and reactive oxygen species (ROS) scavenging. Upon intravenous administration, this streamlined platform exhibits enhanced pulmonary accumulation, effectively silences the profibrotic gene IL11, and suppresses fibroblast-to-myofibroblast transdifferentiation and excessive extracellular matrix deposition. Concurrently, it scavenges overproduced ROS to alleviate oxidative stress-mediated lung damage. Both in vitro and in vivo results demonstrate the potent anti-fibrotic efficacy of PPN@siIL11. By overcoming critical drawbacks of conventional multi-component carriers, this multifunctional single-component platform establishes a translatable approach for RNAi-based IPF therapy, with potential applicability to other lung diseases.

Open article ↗



2026-08-13 | The telomeric DNA damage response as a therapeutic target in idiopathic pulmonary fibrosis.

Telomere dysfunction and the telomeric DNA damage response (tDDR) activation correlate with aging and age-related diseases, including idiopathic pulmonary fibrosis (IPF). However, a causal role for tDDR in IPF pathogenesis has not been determined. IPF patients frequently bear germline mutations in telomerase genes, critically short telomeres, and markers of tDDR and cellular senescence. We previously demonstrated that telomeric antisense-oligonucleotides (tASOs) targeting telomeric non-coding RNAs are selective tDDR inhibitors. Here, we employed late-generation telomerase knockout mice as a genetic model of IPF. Systemic tASOs treatment reduces DDR-including in stem/progenitor cells-inflammation, and lung fibrosis in young, adult, and old mice. Markers of DDR correlate with lung pathology, and tDDR inhibition normalizes molecular and pathological phenotypes, uncoupling telomere lengths from their deleterious consequences. Transcriptomic changes in telomerase knockout mice recapitulate those observed in normal aged mice and in IPF patients, and they are reversed upon tDDR inhibition. These results highlight the pathogenic causative relevance of tDDR activation in IPF pathogenesis and support tASOs as a promising therapeutic strategy for IPF and for telomere biology diseases.

Open article ↗



2026-08-03 | Mannose-modified tobacco mosaic virus-mediated macrophage regulation inhibits pulmonary fibrosis progression.

Idiopathic pulmonary fibrosis (IPF) is a chronic disease, causing irreversible lung scarring and respiratory failure. CD206+ M2 macrophages play a key role in its progression. In this study, we utilize the pro-inflammatory properties of plant viruses to develop a mannose-modified tobacco mosaic virus nanoparticle (TMV-OEG8-Man), which targets and reprograms profibrotic macrophages to inhibit IPF. TMV-OEG8-Man alters the CD206+ M2 macrophage phenotype in vitro, suppressing profibrotic genes (Mrc1, Spp1, Ccr2) and signaling pathways (MAPK, TGF-beta, PI3K-Akt, mTOR, Wnt), thereby reducing the transition of fibroblasts to myofibroblasts. When administered via aerosol, TMV-OEG8-Man achieves prolonged lung retention with minimal systemic exposure. In mice with bleomycin-induced pulmonary fibrosis, a single dose during fibroproliferation attenuated fibrosis progression, increasing survival rate from 50% to 100%, and preserving lung architecture. This study establishes plant viral nanoparticles as a macrophage reprogramming strategy with therapeutic potential for organ fibrosis.

Open article ↗



other
2026-09-18 | Genetically predicted GLP-1R expression and idiopathic pulmonary fibrosis: A Mendelian randomization mediation study of JAKMIP3 and pulmonary function.

ObjectiveTo evaluate the association between genetically predicted GLP-1R expression and idiopathic pulmonary fibrosis and to explore potential mediation through JAKMIP3 and pulmonary-function traits using Mendelian randomization.MethodsWe conducted a two-sample drug-target cis-Mendelian randomization study using Genotype-Tissue Expression lung cis-expression quantitative trait locus summary data as genetic proxies for GLP-1R expression and FinnGen R5 summary data (1028 cases and 196,986 controls; n = 198,014) for idiopathic pulmonary fibrosis. Type 2 diabetes mellitus served as a positive control, and a targeted panel of circulating molecular and pulmonary-function traits was evaluated using two-step Mendelian randomization. Primary estimates were obtained using inverse-variance weighting, with complementary estimators and sensitivity analyses. For the European-ancestry pulmonary function analyses, we used measured forced expiratory volume in 1 s (GCST90691840), forced vital capacity (GCST90691839), and peak expiratory flow (GCST90691841) genome-wide association studies, each including 383,471 participants.ResultsHigher genetically predicted GLP-1R expression was associated with a lower risk of idiopathic pulmonary fibrosis on inverse-variance weighted analysis (odds ratio = 0.740, 95% confidence interval: 0.632-0.866, p = 1.83 × 10-4). The positive-control analysis supported the biological coherence of the GLP1R expression proxy (type 2 diabetes mellitus, odds ratio = 0.630). JAKMIP3 was identified as a candidate circulating protein mediator, with a mediation proportion of 9.8%. In the European-ancestry pulmonary function analyses, forced expiratory volume in 1 s, forced vital capacity, and peak expiratory flow showed mediation proportions of 14.2%, 22.6%, and 11.8%, respectively, with the largest estimate observed for forced vital capacity.ConclusionsThe findings support an association between genetically predicted higher GLP-1R expression and lower risk of idiopathic pulmonary fibrosis and identify JAKMIP3 and pulmonary-function traits as candidate intermediates. These results provide a rationale for mechanistic and clinical studies evaluating glucagon-like peptide-1 receptor-related pathways in idiopathic pulmonary fibrosis.

Open article ↗



2026-09-15 | Integrated Bioinformatics and Experimental Validation to Identify Shared Sialylation-Related Signatures in Emphysematous and Fibrotic Lung Disease.

Emphysema and pulmonary fibrosis represent distinct patterns of chronic lung remodeling but may share molecular and cellular abnormalities. In this study, we analyzed public transcriptomic datasets of chronic obstructive pulmonary disease, emphysema, and idiopathic pulmonary fibrosis from the Gene Expression Omnibus database to explore shared disease-related signatures. Weighted gene co-expression network analysis and differential expression analysis were used to identify common molecular alterations, followed by functional enrichment, protein-protein interaction network construction, hub gene screening, immune infiltration analysis, transcription factor prediction, and single-cell RNA-sequencing validation. The integrated analysis revealed overlapping signatures related to cell adhesion, extracellular matrix organization, vascular regulation, immune responses, and epithelial homeostasis. Five hub genes were validated, and ST6GALNAC5 was further prioritized because of its association with sialylation and predominant enrichment in epithelial cells. Given that sialylation has been rarely investigated in pulmonary fibrosis and emphysema, we therefore further investigated ST6GALNAC5-related epithelial sialylation. Experimental validation on tissue samples showed reduced Sambucus nigra agglutinin lectin signals and decreased ST6GALNAC5 expression in lungs with coexisting emphysematous and fibrotic injury. In vitro experiments confirmed that ST6GALNAC5 overexpression attenuated bleomycin-induced epithelial cell injury. Together, these findings identify convergent molecular signatures across emphysematous and fibrotic lung diseases and suggest that impaired epithelial sialylation may represent a previously underappreciated feature of chronic lung remodeling.

Open article ↗



2026-09-13 | Fibronectin's tensional state as a mechanical signature of fibrotic extracellular matrix in idiopathic pulmonary fibrosis models.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with limited treatment options. Emerging evidence suggests that the composition and mechanics of the extracellular matrix (ECM) play a crucial role in IPF pathogenesis; however, biomarkers that indicate altered ECM signatures are scarce. To demonstrate a direct relationship between ECM fiber tension and fibrosis progression, we established an in vitro fibrosis assay using patient-derived fibroblasts and the tension-sensitive fibronectin-binding peptide FnBPA5, whose multivalent binding to fibronectin is impaired by fiber strain. The system was validated using known fibrosis biomarkers at the protein and mRNA levels. Loss of fibronectin fiber tension not only acts as a marker for fibrosis, but as shown here, tension can be restored upon treatment with antifibrotic drugs, concomitant with improved biomarker data. The loss of fibronectin fiber tension was further corroborated ex vivo by probing fibrotic lung cryosections from bleomycin-treated mice with FnBPA5. Taken together, our results highlight the mechanical state of fibronectin fibers as a promising biomarker for IPF.

Open article ↗



2026-09-02 | Multi-omics integration identifies APOE as a metabolic regulator of macrophage-fibroblast crosstalk in idiopathic pulmonary fibrosis.

Aberrant tissue repair and relentless fibroblast activation are hallmark features of idiopathic pulmonary fibrosis (IPF). Although IPF and Alzheimer's disease (AD) share underlying aging-related pathologies, including immune and metabolic dysregulation, the putative genetic mechanisms linking AD susceptibility to pathogenic macrophage remodeling in the fibrotic niche are not fully established. We performed a two-sample Mendelian randomization (MR) analysis to assess the genetic association and potential causal relationship between AD and IPF. Shared hub genes were identified via protein interaction networks. To characterize macrophage heterogeneity and intercellular crosstalk within the IPF microenvironment, we interrogated scRNA-seq data (GSE122960) utilizing Monocle 3 and CellChat algorithms. The functional essentiality of APOE was evaluated bridging computational virtual knockout (scTenifoldKnk) with laboratory in vitro assays. Specifically, downstream transcriptomic shifts and fibroblast activation capacities were validated using APOE-silenced THP-1 macrophages and a Transwell co-culture model with MRC-5 cells. MR estimates indicated that genetic liability to AD is associated with a lower risk of developing IPF. Integrated profiling identified the lipid-metabolism gene APOE as a central hub, specifically enriched in lung macrophages. Pseudotime modeling captured a pathogenic bifurcation in IPF, where macrophages evolve toward a terminal state marked by profound oxidative phosphorylation defects and massive SPP1 secretion. These SPP1+ macrophages primarily activate fibroblasts via CD44 and integrin signaling axes. Furthermore, both virtual simulations and in vitro THP-1 experiments demonstrated that loss of APOE function triggers the hyperactivation of complement (C1QA) and antigen-presentation (HLA-DR) pathways. Co-culture assays ultimately confirmed that APOE ablation in macrophages strongly exacerbates myofibroblast differentiation (elevated α-SMA and collagen I) in adjacent MRC-5 cells. APOE functions as a vital metabolic barrier against pro-fibrotic macrophage polarization in the lung. Disruption of this specific lipid metabolic network is strongly associated with SPP1-driven fibroblast activation and local immune imbalance, providing a theoretical framework that strictly warrants future in vivo investigation to determine its clinical relevance.

Open article ↗



2026-08-25 | Pulmonary delivery of silk fibroin peptides dry powder inhalers for idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a common disease of pulmonary fibrosis with an increasing incidence. Silk fibroin peptides (SFPs) are bioactive substances rich in essential amino acids and possess antioxidant and anti-inflammatory properties; however, their application is limited by drawbacks such as low bioavailability and susceptibility to protein degradation. In this study, spray-drying technology was employed to prepare a silk fibroin peptides dry powder inhaler (SFPs-DPI), followed by characterisation of its physicochemical properties and preliminary in vitro and in vivo studies. The results showed that the yield of SFPs-DPI was 56.86 ± 1.80%, the Carr's index was 25.64 ± 1.71%, the aerodynamic diameter was 2.26 ± 0.04 μm, the moisture content of 0.74%, and the emptying rate was 93 ± 1.61%. In vitro studies demonstrated that SFPs-DPI exhibits good cellular biocompatibility and antioxidant activity. In vivo pharmacodynamic results showed that SFPs-DPI reduced inflammatory infiltration and collagen fibre deposition in the lungs of IPF mice and reduced the expression of type I collagen and α-SMA in lung tissue. Therefore, the physicochemical properties of the SFPs-DPI prepared in this study meet the relevant requirements for dry powder inhalation formulations, providing a preliminary reference for research related to IPF treatment.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

145 orphan drug designations for Idiopathic pulmonary fibrosis, including 3 approved therapies.

145 orphan drug designations for Idiopathic pulmonary fibrosis, including 3 approved therapies.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

8-oxoguanine DNA glycosylase 1 inhibitor

small molecules

FDA
2026-09-11

—

Oxcia AB

adeno-associated virus vector serotype 6.2 containing human TERT gene

gene therapies

FDA
2026-08-31

—

Telomere Theraperutics SL

4-(4-Bromo-2-oxo-3H-benzimidazol-1-yl)-N-(4-iodophenyl)piperidine-1-carboxamide

small molecules

EMA
2026-08-20

—

Oxcia AB

tazarotene

small molecules

FDA
2026-06-17

Phase II
Completed

GRI Bio Operations, Inc.

tadalafil

small molecules

FDA
2026-03-23

—

Shenzhen Hanhui Pharmaceutical Technology Co., Ltd

small molecule inhibitor of ARG-1 and ARG-2

small molecules

FDA
2026-03-09

Phase II
Ongoing

AstraZeneca Pharmaceuticals LP

tranilast lysate

small molecules

FDA
2026-03-09

—

Nuformix Technologies Limited

deupirfenidone

small molecules

FDA
2026-02-19

Phase III
Ongoing

PureTech LYT 100, Inc., a subsidiary of PureTech Health plc

isoquinoline derivative containing diesters that inhibits BCL-xL

small molecules

FDA
2026-01-15

Phase I
Ongoing

Nanjing Reju Therapeutics Co., Ltd.

Phe-Thr-Thr-Phe-Thr-Val-Thr

peptides

EMA
2026-01-09

Phase II
Ongoing

Scendea (NL) B.V.

Deupirfenidone

small molecules

EMA
2026-01-09

Phase III
Ongoing

Granzer Regulatory Consulting & Services GmbH

humanised monoclonal antibody-drug conjugate delivering an mTOR inhibitor payload

antibodies

FDA
2025-12-09

—

Bionevix Ltd

Adeno-associated virus vector serotype 6.2 containing human TERT gene

gene therapies

EMA
2025-12-09

—

Telomere Therapeutics S.L.

zampilimab

antibodies

FDA
2025-11-25

Phase II
Ongoing

Chiesi Farmaceutici S.p.A.

Orvepitant maleate

small molecules

EMA
2025-11-21

Phase II
Completed

Granzer Regulatory Consulting & Services GmbH

kynurenic acid

small molecules

FDA
2025-11-14

—

BirchBioMed Inc.

a humanized anti-S100A4 monoclonal antibody of immunoglobulin G4 isotype

antibodies

FDA
2025-10-24

Phase II
Ongoing

Calluna Pharma AS

roflumilast

small molecules

FDA
2025-09-03

—

Transpire Bio Inc

Admilparant

small molecules

EMA
2025-08-22

Phase III
Ongoing

Bristol-Myers Squibb Pharma EEIG

taladegib

small molecules

FDA
2025-06-18

Phase II
Ongoing

Endeavor Biomedicines

Taladegib

small molecules

EMA
2025-05-22

Phase II
Ongoing

Orphix Consulting GmbH

Tranilast

small molecules

EMA
2025-05-22

—

Boyd Consultants Limited

orvepitant

small molecules

FDA
2025-04-04

Phase II
Completed

NeRRe Therapeutics Ltd

selective CXCR7 agonist

small molecules

FDA
2025-02-12

—

iLeadBMS Co., Ltd.

an autologous cell product derived from the human airway basal cells without any gene modification

cell therapies

FDA
2025-02-04

Phase II
Completed

Regend Therapeutics Co., Ltd.

artesunate

small molecules

FDA
2024-11-18

—

Artasome Therapeutics, LLC

fluoro methyl gallocatechin gallate

small molecules

FDA
2024-07-18

—

Avanti Biosciences, Inc.

Humanized immunoglobulin G1 monoclonal antibody directed against WNT1-inducible signaling pathway protein-1

antibodies

FDA
2024-07-08

Phase II
Ongoing

Mediar Therapeutics, Inc.

Nerandomilast

small molecules

EMA
2024-06-28

Phase III
Ongoing

Boehringer Ingelheim International GmbH

Zinc (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate and (3S,9aS)-3-(1H-imidazol-5-ylmethyl)-octahydro-1H-pyrido[1,2-a]piperazine-1,4-dione

small molecules

FDA
2024-05-30

—

NovMetaPharma Co., Ltd.

lixudebart

antibodies

FDA
2024-05-24

—

Alentis Therapeutics AG

2-(Piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)benzoate

small molecules

FDA
2024-05-15

Phase I
Completed

AgomAb Spain, S.L.

immunomodulatory inhibitor of high mobility group box 1

antibodies

FDA
2024-02-22

Phase II
Ongoing

Spark Biopharma, Inc.

Bersiporocin

small molecules

EMA
2023-12-13

Phase II
Ongoing

Propharma Group The Netherlands B.V.

Pyridine derivative containing pyridazine that inhibits lysophospholipase

small molecules

FDA
2023-11-08

Phase II
Completed

Boehringer Ingelheim Pharmaceuticals, Inc.

zelasudil

small molecules

FDA
2023-08-14

Phase II
Ongoing

Redx Pharma Plc

Human Umbilical Cord-derived Mesenchymal Stem Cell Injection

cell therapies

FDA
2023-08-09

Phase I
Completed

Wuhan Optics Valley Vcanbiopharma Co., Ltd.

(R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl] amino}thiophen-2-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid

small molecules

FDA
2023-06-12

—

HiLung, Inc.

a humanized, immunoglobulin G subtype 4 anti-Amphiregulin monoclonal antibody

antibodies

FDA
2023-02-16

Phase I
Completed

Pulmongene (Hong Kong) Co., Limited

imidazole derivative

small molecules

FDA
2023-02-01

Phase II
Completed

InSilico Medicine Hong Kong Limited

Piperidine-containing autotaxin inhibitor

small molecules

FDA
2023-01-19

—

NextGen Bioscience

Ivaltinostat

small molecules

FDA
2023-01-03

—

Machaon Biotherapeutics, Inc.

(H-L-Arginyl-L-Valyl-L-Isoleucyl-L-Arginyl-L-Alanyl-L-Cysteinyl-L-Leucyl-Glycyl-L-Valyl-Glycyl-L-Leucyl-L-Leucyl-Glycyl-L-Asparaginyl-L-Leucyl-D-Alanyl-Glycyl-L-Lysyl-amino-PEG12-propionic acid)2 (Disulfide bond at Cys)

proteins

FDA
2022-12-13

—

CohBar, Inc.

Bexotegrast

small molecules

EMA
2022-12-09

Phase II/III
Terminated

Pharma Gateway AB

ifenprodil

small molecules

FDA
2022-12-01

Phase II
Terminated

Algernon Pharmaceuticals Inc.

garadacimab

antibodies

FDA
2022-08-16

Phase II
Completed

CSL Behring

Ex-vivo conditioned medium from cultured adult human mesenchymal stem cells

other

FDA
2022-08-15

—

Summa Bio-Solutions Inc.

nerandomilast [Jascayd]

small molecules

FDA
2022-08-15

Approved
2025-10-07

Boehringer Ingelheim Pharmaceuticals, Inc.

4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulfonamide

small molecules

FDA
2022-08-15

Phase II
Terminated

Modern Biosciences Ltd

Selective Colony Stimulating Factor-1 Receptor kinase inhibitor

antibodies

FDA
2022-07-27

—

Elixiron Immunotherapeutics Inc.

Pirfenidone

small molecules

EMA
2022-06-24

Phase III
Completed

Regintel Limited

(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)-8-(quinolin-5-ylmethyl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide methane sulfonic acid

small molecules

FDA
2022-06-07

—

3Plus2 Pharma, LLC

Chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment

peptides

EMA
2022-05-16

—

JVM Europe B.V.

N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide

small molecules

FDA
2022-04-19

Phase II
Completed

Tvardi Therapeutics, Inc.

Treprostinil sodium

small molecules

EMA
2022-03-16

Phase III
Completed

Ferrer Internacional S.A.

((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)

small molecules

FDA
2022-03-08

—

APIE Therapeutics

glucagon-like peptide-1/glucagon/gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment

proteins

FDA
2021-05-10

—

Hanmi Pharmaceutical Co., Ltd.

axatilimab

antibodies

FDA
2021-04-07

Phase II
Ongoing

Syndax Pharmaceuticals, Inc.

lithium carbonate

small molecules

FDA
2021-03-29

—

Lispiro LLC

Sodium-3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoate

small molecules

FDA
2021-02-23

Phase II
Terminated

Blade Therapeutics, Inc.

Fc-fusion protein comprised of an anti-CXCR4 i-body tethered at its C-terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1

proteins

FDA
2021-02-22

—

AdAlta Limited

N-(N-(4-(trifluoromethoxy)phenyl) carbamimidoyl)pyrrolidine-1-carboximidamide acetate (Or N1-(4-trifluoromethoxy)phenyl-N5-pyrrolidine biguanide acetate)

small molecules

FDA
2021-02-01

—

ImmunoMet Therapeutics Inc.

Treprostinil

small molecules

FDA
2020-12-07

Phase III
Ongoing

United Therapeutics Corporation

Caveolin-1 Scaffolding Domain 7-Mer

peptides

FDA
2020-09-09

Phase II
Ongoing

Lung Therapeutics, Inc.

Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-B-D-galactopyranosyl) sulfane

small molecules

FDA
2020-08-25

Phase II
Terminated

Galecto Biotech AB

Olitigaltin

small molecules

EMA
2020-08-21

Phase II
Terminated

Galecto Biotech AB

Sodium cromoglicate

small molecules

EMA
2020-06-26

Phase II
Terminated

IQVIA RDS Spain S.L.

Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-

small molecules

FDA
2020-05-18

—

Amplia Therapeutics

4-fluoro-5-((6-methylhexahydropyrrolo[3,4-b] pyrrol-5(1H)-yl) sulfonyl) isoquinoline

small molecules

FDA
2020-02-05

Phase I
Terminated

The National Institutes of Pharmaceutical R&D Co., Ltd

drug component, inhaled nitric oxide, of the inhaled nitric oxice/INOpulse® Device combination product

small molecules

FDA
2019-09-10

Phase II
Terminated

Mallinckrodt Pharmaceuticals Ireland Limited

(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol Hydrogen Chloride

small molecules

FDA
2019-08-05

Phase II
Ongoing

Daewoong Pharmaceutical Co., Ltd.

N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide

small molecules

FDA
2019-07-22

Phase I
Terminated

Blade Therapeutics, Inc.

(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4,5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide

small molecules

FDA
2019-07-18

—

X-Rx, Inc.

(6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone

small molecules

FDA
2019-05-08

Phase III
Ongoing

Beijing Tide Pharmaceutical Co., Ltd

cromolyn solution

small molecules

FDA
2019-04-11

Phase I
Terminated

Respivant Sciences, Inc.

saracatinib

small molecules

FDA
2019-03-11

Phase I/II
Ongoing

AstraZeneca Pharmaceuticals, LP

5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine

small molecules

FDA
2019-02-25

—

Molecure S.A. (previously OncoArendi S.A.)

Autotaxin inhibitor

small molecules

FDA
2019-01-14

Phase II
Completed

Bridge Biotherapeutics, Inc

small interfering RNA agent that targets human transforming growth factor-Eszett1 messenger RNA

RNAs

FDA
2018-12-19

Phase I
Terminated

Toray Industries, Inc.

15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester

small molecules

FDA
2018-12-17

—

Afimmune

(1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid

small molecules

FDA
2018-12-17

Phase III
Ongoing

Bristol-Myers Squibb Company

5-(3,5-Dimethyl-4-hydroxybenzylamino)-3-(4-morpholin-4-yl-phenylamino)-1H-pyrazole-4-carboxylic acid amide

small molecules

FDA
2018-12-07

Phase I
Terminated

Metagone Biotech Inc.

Tilorone

small molecules

EMA
2018-08-24

—

Professor Marjukka Myllärniemi

(S)-(-)-3-(4-aminophenyl)-2-methoxypropanoic acid

small molecules

EMA
2018-08-24

—

Nogra Pharma Limited

small molecule inhibitor of integrins avb6 and avb1

small molecules

FDA
2018-08-01

Phase II
Terminated

Pliant Therapeutics, Inc.

soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide

small molecules

FDA
2018-07-09

Phase I
Terminated

Sunshine Lake Pharma Co., Ltd

small molecule selective inhibitor of c-Jun N-terminal kinase

small molecules

FDA
2018-06-27

Phase II
Terminated

Celgene Corporation

N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide

small molecules

FDA
2018-05-23

—

Arroyo Biosciences, LLC

6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride

small molecules

FDA
2018-04-04

—

Reviva Pharmaceuticals, Inc.

plasminogen (Human)

proteins

FDA
2017-12-14

—

Kedrion Biopharma Inc.

yinfenidone

small molecules

FDA
2017-08-10

Phase III
Ongoing

Sunshine Lake Pharma Co., Ltd

2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile

small molecules

FDA
2017-06-08

Phase III
Terminated

Galapagos NV

small molecule inhibitor of the Wnt pathway

small molecules

FDA
2017-06-06

—

Biosplice Therapeutics, Inc.

nitric oxide

small molecules

FDA
2017-01-31

Phase II
Terminated

VERO Biotech

3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt

small molecules

FDA
2017-01-25

Phase II
Ongoing

Vicore Pharma AB

human single domain antibody-like protein inhibitor of the chemokine receptor type 4

antibodies

FDA
2017-01-11

—

AdAlta Limited

Ziritaxestat [GLPG1690]

small molecules

EMA
2016-08-29

Phase III
Terminated

Lakefront Biotherapeutics

carbon monoxide

small molecules

FDA
2016-08-16

Phase II
Terminated

Proterris, Inc.

3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt

small molecules

EMA
2016-07-14

Phase II
Ongoing

Vicore Pharma AB

monoclonal antibody targeting eotaxin-2

antibodies

FDA
2015-10-29

—

ChemomAb, Ltd.

Setogepram sodium [PBI-4050]

small molecules

EMA
2015-10-09

Phase II
Terminated

[INACTIVE] Prometic Pharma SMT B.V.

tetra-substituted porphyrin derivative containing manganese (III)

small molecules

FDA
2015-03-16

—

Aeolus Pharmaceuticals

lebrikizumab

antibodies

FDA
2015-03-09

Phase II
Terminated

Eli Lilly and Company

3-pentylbenzenacetic acid sodium salt

small molecules

FDA
2015-02-11

Phase II
Terminated

Liminal BioSciences Limited

1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid

small molecules

EMA
2014-11-19

—

Inventiva

tipelukast

small molecules

FDA
2014-10-20

Phase II
Terminated

MediciNova, Inc.

pirfenidone

small molecules

FDA
2014-07-31

Phase III
Terminated

Avalyn Pharma, Inc.

Humanised anti-alpha ν beta 6 monoclonal antibody

antibodies

EMA
2014-07-29

Phase II
Terminated

Biogen Netherlands B.V.

Nintedanib esylate [Ofev]

small molecules

EMA
2013-04-26

Phase III
Terminated

Boehringer Ingelheim International GmbH

Tralokinumab [CAT-354]

antibodies

EMA
2012-11-08

Phase II
Terminated

Medimmune Limited

tralokinumab

antibodies

FDA
2012-07-24

Phase II
Terminated

MedImmune Ltd.

Recombinant human pentraxin-2

proteins

EMA
2012-07-17

Phase III
Terminated

Roche Registration GmbH

pamrevlumab

antibodies

FDA
2012-07-06

Phase III
Terminated

FibroGen, Inc.

recombinant human Pentraxin-2; recombinant human Serum Amyloid P

proteins

FDA
2012-02-17

Phase III
Terminated

Genentech, Inc.

Tanzisertib [CC-930]

small molecules

EMA
2011-12-09

Phase II
Terminated

Celgene Europe Limited

4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol

small molecules

FDA
2011-09-23

Phase II
Terminated

Celgene Corporation

bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)

antibodies

FDA
2011-09-14

Phase II
Terminated

Sanofi US Services, Inc., A SANOFI COMPANY

nintedanib [OFEV]

small molecules

FDA
2011-06-29

Approved
2014-10-15

Boehringer Ingelheim Pharmaceuticals, Inc.

Recombinant humanized anti-LOXL2 monoclonal antibody

antibodies

FDA
2011-04-18

Phase II
Terminated

Gilead Sciences, Inc.

(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt

small molecules

FDA
2011-04-15

Phase II
Terminated

Bristol-Myers Squibb Company

Sar9, Met(O2)11-Substance P

proteins

FDA
2011-03-16

—

New Amsterdam Sciences

2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione

small molecules

EMA
2010-11-26

Phase II
Completed

Calliditas Therapeutics AB

Ambrisentan [ABS-10-001]

small molecules

EMA
2010-10-01

Phase III
Terminated

Gilead Sciences International Limited

2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione

small molecules

FDA
2010-09-21

Phase II
Completed

Calliditas Therapeutics AB

humanized monoclonal antibody against human integrin alphaVbeta6

antibodies

FDA
2010-08-05

Phase II
Terminated

Biogen Idec, Inc.

Cintredekin Besudotox

proteins

FDA
2010-04-30

—

Insys Development Company, Inc.

Macitentan [Opsumit]

small molecules

EMA
2010-01-28

Phase II
Terminated

Janssen Cilag International

ambrisentan

small molecules

FDA
2009-12-23

Phase III
Terminated

Gilead Sciences, Inc.

purified bovine type collagen

proteins

FDA
2009-04-27

Phase II
Completed

Magnolia Therapeutics LLC

macitentan

small molecules

FDA
2009-04-14

Phase II
Terminated

Actelion Pharmaceuticals Ltd

bosentan

small molecules

FDA
2008-09-30

Phase III
Terminated

Actelion Pharmaceuticals Ltd

Bosentan monohydrate [Tracleer]

small molecules

EMA
2008-09-05

Phase III
Terminated

[INACTIVE] Actelion Registration Limited

ammonium tetrathiomolybdate

small molecules

FDA
2008-05-05

—

Pipex Pharmaceuticals, Inc.

Fresolimumab

antibodies

EMA
2008-04-01

Phase I
Terminated

[INACTIVE] Sanofi B.V.

carlumab

antibodies

FDA
2007-11-08

Phase II
Terminated

Janssen Biotech, Inc.

Interferon gamma

proteins

EMA
2007-10-29

Phase III
Terminated

mondoBIOTECH Laboratories AG

Interferon gamma

proteins

FDA
2007-10-11

Phase III
Terminated

mondoBIOTECH Laboratories AG

Interferon gamma-1B

proteins

EMA
2005-05-27

Phase III
Terminated

Intermune UK Limited

Acetylcysteine

small molecules

EMA
2005-01-26

Phase III
Terminated

Zambon Group S.p.A.

Pirfenidone [Esbriet]

small molecules

EMA
2004-11-16

Phase III
Terminated

Roche Registration GmbH

Heparin sodium [FibroCure]

other

EMA
2004-09-02

—

Werner Seeger

human anti-transforming growth factor-B1,2,3

antibodies

FDA
2004-07-09

Phase I
Terminated

Genzyme Corporation

pirfenidone [ESBRIET]

small molecules

FDA
2004-03-05

Approved
2014-10-15

Legacy Pharma Inc.

interferon gamma-1b

proteins

FDA
2002-09-12

Phase III
Terminated

InterMune, Inc.

Interferon beta-1a (recombinant human)

proteins

FDA
1999-01-07

—

Biogen Idec, Inc.

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.